Latham & Watkins Advises Mesoblast in Refinancing and Expansion of Senior Debt Facility with Oaktree Capital

A multidisciplinary deal team represented the lead developer of stem cell medicines for the treatment of inflammatory conditions.

November 29, 2021

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in stem cell medicines for inflammatory diseases, has announced that it has successfully refinanced its existing senior debt facility with a new US$90 million five year facility, along with the issuance of warrants, with funds managed by Oaktree Capital Management, L.P.

Latham & Watkins LLP represented Mesoblast in the transaction with a deal team led by Bay Area finance partner Haim Zaltzman, with associates Ramin Montazeri, Trevor Church, and Reena Sahota. Advice was also provided on UK tax matters by London partner Karl Mah, with associates Edward Moberly and Mimi Kyprianou; on US tax matters by Los Angeles partner Eric Cho, with associate Sam Yang; on UK finance matters by London partner James Chesterman, with associates Hafza Hussein and Timi Afolami; on capital markets matters by New York partner Reza Mojtabaee-Zamani, with associate Jack Neff; and on regulatory matters by Washington, D.C. associate Chad Jennings. 

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.